One of the biotech companies run by Martin Shkreli, the reviled drug price-gouger charged with securities fraud last week, was informed on Wednesday that its stock was to be delisted by NASDAQ because of Shkreli’s arrest and other issues.
Meanwhile, KaloBios Pharmaceuticals Inc also is dealing with the abrupt resignation of its accounting firm and a void left by its firing of Shkreli.
KaloBios was running out of money and planning to suspend its research programs and shut down operations last month. That is when Shkreli, the chief executive of Turing Pharmaceuticals Inc, swooped and gained a controlling interest in the company. Shkreli was immediately named chief executive and chairman of the board of the South San Francisco, California, drug developer.
Photo: Reuters
In a statement on Wednesday, KaloBios said that NASDAQ wrote that it would be removed from trading on Wednesday next week if KaloBios does not appeal. The company has not yet decided whether it would appeal.
NASDAQ cited reasons for the delisting including the indictment and arrest of both Shkreli and an outside attorney for KaloBios, Evan Greebel, plus the company’s noncompliance with financial reporting rules. KaloBios has not filed with the US Securities and Exchange Commission (SEC) a report on its financial results for the three months ended Sept. 30, as publicly traded companies are required to do every three months.
Shkreli became notorious after hiking the price of Daraprim, the only approved drug for toxoplasmosis, a rare and sometimes deadly parasitic infection, by 5,000 percent — from US$13.50 to US$750 per pill. Shkreli has been deluged with criticism from patients, politicians and others since hiking Daraprim’s price late in the summer, shortly after the US rights to sell it were bought by Turing, a biotech company Shkreli founded last year.
On Thursday last week, Shkreli, a 32-year-old former hedge fund manager, was arrested in New York and charged with securities fraud and conspiracy related to a pharmaceutical company he previously ran called Retrophin.
Federal prosecutors allege that from 2009 to last year, Shkreli made bad trades that lost money for some investors in his hedge fund, MSMB Capital Management. Prosecutors say he then looted Retrophin for US$11 million to pay back his disgruntled clients.
Shkreli has pleaded not guilty and said that he was targeted for increasing Daraprim’s price. He was released on US$5 million bail on Thursday last week.
Greebel was charged with conspiracy and also pleaded not guilty. The two men face similar allegations in a civil complaint filed by the SEC.
KaloBios fired Shkreli as chief executive and he resigned from its board on Thursday last week, though the company did not announce that until Monday. Also on Monday, its independent registered public accounting firm, Marcum LLP, resigned as the independent accounting firm for KaloBios, less than two weeks after being retained on Dec. 8.
KaloBios has not announced who is to serve as chief executive and chairman, and it has not responded to questions on the subject by The Associated Press. Its stock has not traded since Wednesday last week, when its shares closed at US$23.59.
Shkreli resigned on Friday last week as chief executive of Turing, which has offices in New York and Zug, Switzerland.
Stephen Garrett, a 27-year-old graduate student, always thought he would study in China, but first the country’s restrictive COVID-19 policies made it nearly impossible and now he has other concerns. The cost is one deterrent, but Garrett is more worried about restrictions on academic freedom and the personal risk of being stranded in China. He is not alone. Only about 700 American students are studying at Chinese universities, down from a peak of nearly 25,000 a decade ago, while there are nearly 300,000 Chinese students at US schools. Some young Americans are discouraged from investing their time in China by what they see
MAJOR DROP: CEO Tim Cook, who is visiting Hanoi, pledged the firm was committed to Vietnam after its smartphone shipments declined 9.6% annually in the first quarter Apple Inc yesterday said it would increase spending on suppliers in Vietnam, a key production hub, as CEO Tim Cook arrived in the country for a two-day visit. The iPhone maker announced the news in a statement on its Web site, but gave no details of how much it would spend or where the money would go. Cook is expected to meet programmers, content creators and students during his visit, online newspaper VnExpress reported. The visit comes as US President Joe Biden’s administration seeks to ramp up Vietnam’s role in the global tech supply chain to reduce the US’ dependence on China. Images on
New apartments in Taiwan’s major cities are getting smaller, while old apartments are increasingly occupied by older people, many of whom live alone, government data showed. The phenomenon has to do with sharpening unaffordable property prices and an aging population, property brokers said. Apartments with one bedroom that are two years old or older have gained a noticeable presence in the nation’s six special municipalities as well as Hsinchu county and city in the past five years, Evertrust Rehouse Co (永慶房產集團) found, citing data from the government’s real-price transaction platform. In Taipei, apartments with one bedroom accounted for 19 percent of deals last
US CONSCULTANT: The US Department of Commerce’s Ursula Burns is a rarely seen US government consultant to be put forward to sit on the board, nominated as an independent director Taiwan Semiconductor Manufacturing Co (TSMC, 台積電), the world’s largest contract chipmaker, yesterday nominated 10 candidates for its new board of directors, including Ursula Burns from the US Department of Commerce. It is rare that TSMC has nominated a US government consultant to sit on its board. Burns was nominated as one of seven independent directors. She is vice chair of the department’s Advisory Council on Supply Chain Competitiveness. Burns is to stand for election at TSMC’s annual shareholders’ meeting on June 4 along with the rest of the candidates. TSMC chairman Mark Liu (劉德音) was not on the list after in December last